Docetaxel - Carboplatin as Second Line Treatment in Patients With Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Phase II studies with docetaxel in first line - and second line treatment of SCLC
demonstrated that docetaxel is an active agent in these patient groups. Therefore docetaxel
seems suitable for evaluation in combination with other cytotoxic drugs active in this
disease. A phase II study in previously untreated patients with SCLC shows that the
combination docetaxel and cisplatin/carboplatin is an active and well tolerated regimen in
extensive SCLC.